Vol 47, No 1 (2009)
Original paper
Published online: 2009-05-08

open access

Page views 2683
Article views/downloads 2694
Get Citation

Connect on Social Media

Connect on Social Media

Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.

Bozena Dobrzycka, Sławomir J Terlikowski, Andrzej Mazurek, Oksana Kowalczuk, Wiesława Niklińska, Lech Chyczewski, Marek Kulikowski
DOI: 10.2478/v10042-009-0014-2
Folia Histochem Cytobiol 2009;47(1):65-68.

Abstract

The aim of this study was to examine the prevalence and clinicopathological significance of KRAS point mutation in endometrial hyperplasia and carcinoma. We analysed KRAS in 11 cases of complex atypical hyperplasia and in 49 endometrial carcinomas using polymerase chain reaction associated with restriction fragment length polymorphism (PCR-RFPL). Point mutations at codon 12 of KRAS oncogene were identified in 7 of 49 (14,3%) tumor specimens and in 2 of 11 (18,2%) hyperplasias. No correlation was found between KRAS gene mutation and age at onset, histology, grade of differentiation and clinical stage. We conclude that KRAS mutation is a relatively common event in endometrial carcinogenesis, but with no prognostic value.

Article available in PDF format

View PDF Download PDF file



Folia Histochemica et Cytobiologica